Will CosMc’s Take Off? Social Media Response Could Determine the New McDonald’s Subbrand’s Fate

 

McDonald’s latest experiment in the customizable drink and coffee market could make a cosmic splash in the industry if the social media response to the concept turns out positive.

McDonald’s is introducing its CosMc’s spinoff in Bolingbrook, Illinois, a new venture combining a unique, beverage-led menu with classic and innovative offerings. This small-format concept, primarily targeting the $100 billion customizable drink and coffee market, features a range of customizable drinks, specialty coffees, and snack options designed to cater to afternoon cravings. The launch of CosMc’s, part of McDonald’s broader expansion strategy, aims to test the market with 10 locations, focusing on areas like Dallas-Fort Worth and San Antonio.

Emphasizing customer convenience, CosMc’s integrates a digital and Drive-Thru experience for a suite of bold, personalized beverage selections and a select range of food items. This initiative represents McDonald’s latest effort to create a distinctive, customer-centric dining experience, with its success potentially guiding further expansion.

Is McDonald’s expansion into the low-end, beverage-driven QSR market with CosMc’s a strategic move to compete against established coffee giants, and what factors will influence its success in this new venture?

Laura Murphy, Senior Vice President at Bolt PR, provides insightful analysis of McDonald’s foray, highlighting the brand’s evolution and potential impact in the current social media-driven market landscape. Murphy has 10+ years of experience working on branding & marketing strategies for major chains like McDonalds, Chick-fil-A, Chuy’s Tex Mex and Bonefish Grill.

“McDonald’s is able to do the same thing [as Starbucks], but now they’re taking it a step further and creating a sub-concept in addition to one that is just so well known… that word-of-mouth is everything,” Murphy said. “People use social media to determine whether or not they want to try something.”

Article by James Kent

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More